ATLANTA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that
specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it
intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market
conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of
the offering. Alimera also expects to grant the underwriters a 30-day option to purchase additional shares of common stock at
the public offering price to cover over-allotments, if any. All of the shares in the offering are to be sold by Alimera, with
net proceeds to be used to fund the continued commercialization of ILUVIEN® and for working capital and other general
corporate purposes.
Cowen and Company, LLC is acting as the sole managing underwriter for the offering.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above
was filed with the Securities and Exchange Commission (SEC) on August 11, 2014 and declared effective by the SEC on August 20,
2014. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the
registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with
the SEC and will be available on the SEC’s web site at www.sec.gov. When available, copies of the preliminary prospectus supplement relating to these
securities may also be obtained by sending a request to: Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not
permitted.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization
of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies and affect millions of people in aging populations.
Alimera’s European operations are conducted from London by its subsidiary, Alimera Sciences Limited, which has offices in
Aldershot, United Kingdom, Berlin, Germany and Lisbon, Portugal.
Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act
of 1995, regarding, among other things, the proposed public offering of Alimera’s common stock. Such forward-looking statements are
based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change
any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful
factors which could cause actual results to differ, including, whether or not Alimera will be able to raise capital, the final
terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the
proposed public offering, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31,
2015 and Alimera’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, which are on file with the
Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Alimera’s Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable
factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by
Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on,
Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be
achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements
contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes
or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another
date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any
such forward-looking statements, whether as a result of new information, future events or otherwise.
For press inquiries: Katie Brazel for Alimera Sciences 404-317-8361 kbrazel@bellsouth.net For investor inquiries: CG Capital for Alimera Sciences 877-889-1972 investorrelations@cg.capital